Researchers develop a 3D-printed, RNA-activated implant that silences the PTEN gene to promote nerve regrowth after spinal cord injury.
MedPage Today on MSN
In-Utero Repair of Severe Spina Bifida With Stem Cells Shows Promise
A first in-human, phase I trial examined feasibility as well as safety ...
A new human spinal cord organoid model replicates key injury responses, such as inflammation, cell loss, and scar formation.
Interesting Engineering on MSN
Breakthrough human spinal cord organoids revive hope for paralysis repair
Scientists at Northwestern University have built what they call the most advanced human spinal ...
A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery ...
Sycamore Bark Thoroughbreds owner Dan Davidson recalls the excitement of watching Save the Trees, who he bred, become a ...
Erectile dysfunction can indicate heart disease years before cardiovascular issues arise. In fact, most heart problems don’t ...
NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...
A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...
A dual-compound strategy rewires the injured spinal cord. This graphic shows how a paired therapy combining luteolin (Lut) and astragaloside IV (AST)—two bioactive compounds derived from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results